nach oben

Erschienen in:

15.11.2017 | Original Article

Etoposide Upregulates Survival Favoring Sphingosine-1-Phosphate in Etoposide-Resistant Retinoblastoma Cells

verfasst von: Vinodh Kakkassery, S. Skosyrski, A. Lüth, B. Kleuser, M. van der Giet, R. Tate, J. Reinhard, A. Faissner, S. C. Joachim, N. Kociok

Erschienen in: Pathology & Oncology Research | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Improved knowledge of retinoblastoma chemotherapy resistance is needed to raise treatment efficiency. The objective of this study was to test whether etoposide alters glucosyl-ceramide, ceramide, sphingosine, and sphingosine-1-phosphate (sphingosine-1-P) levels in parental retinoblastoma cells (WERI Rb1) or their etoposide-resistant subclones (WERI EtoR). WERI Rb1 and WERI EtoR were incubated with 400 ng/ml etoposide for 24 h. Levels of glucosyl-ceramides, ceramides, sphingosine, sphingosine-1-P were detected by Q-TOF mass spectrometry. Statistical analysis was done by ANOVA followed by Tukey post-hoc test (p < 0.05). The mRNA expression of sphingolipid pathways enzymes in WERI Rb1, WERI EtoR and four human retinoblastoma tissue samples was analyzed by quantitative real-time PCR. Pathways enzymes mRNA expression confirmed similarities of human sphingolipid metabolism in both cell lines and tissue samples, but different relative expression. Significant up-regulation of sphingosine was seen in both cell lines (p < 0.001). Only sphingosine-1-P up-regulation was significantly increased in WERI EtoR (p < 0.01), but not in WERI Rb1 (p > 0.2). Both cell lines upregulate pro-apoptotic sphingosine after etoposide incubation, but only WERI EtoR produces additional survival favorable sphingosine-1-P. These data may suggest a role of sphingosine-1-P in retinoblastoma chemotherapy resistance, although this seems not to be the only resistance mechanism.

Sanders BM, Draper GJ, Kingston JE (1988) Retinoblastoma in Great Britain 1969-80: incidence, treatment, and survival. Br J Ophthalmol 72(8):576–583CrossRefPubMedPubMedCentral

Abramson DH, Schefler AC (2004) Update on retinoblastoma. Retina 24(6):828–848CrossRefPubMed

Schuler AO, Bornfeld N (2000) Current therapy aspects of intraocular tumors. Ophthalmologe 97(3):207–222CrossRefPubMed

Shields CL, De Potter P, Himelstein BP, Shields JA, Meadows AT, Maris JM (1996) Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol 114(11):1330–1338CrossRefPubMed

Friedman DL, Himelstein B, Shields CL, Shields JA, Needle M, Miller D et al (2000) Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 18(1):12–17CrossRefPubMed

Toma NM, Hungerford JL, Plowman PN, Kingston JE, Doughty D (1995) External beam radiotherapy for retinoblastoma: II. Lens sparing technique. Br J Ophthalmol 79(2):112–117CrossRefPubMedPubMedCentral

Hungerford JL, Toma NM, Plowman PN, Doughty D, Kingston JE (1997) Whole-eye versus lens-sparing megavoltage therapy for retinoblastoma. Front Radiat Ther Oncol 30:81–87CrossRefPubMed

Abramson DH, Marr BP, Dunkel IJ, Brodie S, Zabor EC, Driscoll SJ et al (2012) Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results. Br J Ophthalmol 96(4):499–502CrossRefPubMed

Shields CL, Manjandavida FP, Lally SE, Pieretti G, Arepalli SA, Caywood EH et al (2014) Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology 121(7):1453–1460CrossRefPubMed

10.

Munier FL, Beck-Popovic M, Balmer A, Gaillard MC, Bovey E, Binaghi S (2011) Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma. Retina 31(3):566–573CrossRefPubMed

11.

Hannun YA, Obeid LM (2008) Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 9(2):139–150CrossRefPubMed

12.

Li W, Yu CP, Xia JT, Zhang L, Weng GX, Zheng HQ et al (2009) Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res 15(4):1393–1399CrossRefPubMed

13.

French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL et al (2003) Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 63(18):5962–5969PubMed

14.

Johnson KR, Johnson KY, Crellin HG, Ogretmen B, Boylan AM, Harley RA et al (2005) Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue. J Histochem Cytochem 53(9):1159–1166CrossRefPubMed

15.

Li J, Guan HY, Gong LY, Song LB, Zhang N, Wu J et al (2008) Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. Clin Cancer Res 14(21):6996–7003CrossRefPubMed

16.

Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ, Prior TW (2005) Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol 64(8):695–705CrossRefPubMed

17.

Kohno M, Momoi M, Oo ML, Paik JH, Lee YM, Venkataraman K et al (2006) Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol Cell Biol 26(19):7211–7223CrossRefPubMedPubMedCentral

18.

Kawamori T, Kaneshiro T, Okumura M, Maalouf S, Uflacker A, Bielawski J et al (2009) Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J 23(2):405–414CrossRefPubMedPubMedCentral

19.

Bayerl MG, Bruggeman RD, Conroy EJ, Hengst JA, King TS, Jimenez M et al (2008) Sphingosine kinase 1 protein and mRNA are overexpressed in non-Hodgkin lymphomas and are attractive targets for novel pharmacological interventions. Leuk Lymphoma 49(5):948–954CrossRefPubMed

20.

Ruckhaberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S et al (2008) Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 112(1):41–52CrossRefPubMed

21.

Erez-Roman R, Pienik R, Futerman AH (2010) Increased ceramide synthase 2 and 6 mRNA levels in breast cancer tissues and correlation with sphingosine kinase expression. Biochem Biophys Res Commun 391(1):219–223CrossRefPubMed

22.

Grammatikos G, Teichgraber V, Carpinteiro A, Trarbach T, Weller M, Hengge UR et al (2007) Overexpression of acid sphingomyelinase sensitizes glioma cells to chemotherapy. Antioxid Redox Signal 9(9):1449–1456CrossRefPubMed

23.

Morita Y, Perez GI, Paris F, Miranda SR, Ehleiter D, Haimovitz-Friedman A et al (2000) Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med 6(10):1109–1114CrossRefPubMed

24.

Lacour S, Hammann A, Grazide S, Lagadic-Gossmann D, Athias A, Sergent O et al (2004) Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res 64(10):3593–3598CrossRefPubMed

25.

Akao Y, Banno Y, Nakagawa Y, Hasegawa N, Kim TJ, Murate T et al (2006) High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation. Biochem Biophys Res Commun 342(4):1284–1290CrossRefPubMed

26.

Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, Garcia V et al (2005) Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res 65(24):11667–11675CrossRefPubMed

27.

Guillermet-Guibert J, Davenne L, Pchejetski D, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C et al (2009) Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Ther 8(4):809–820CrossRefPubMed

28.

Baran Y, Salas A, Senkal CE, Gunduz U, Bielawski J, Obeid LM et al (2007) Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem 282(15):10922–10934CrossRefPubMed

29.

Stephan H, Boeloeni R, Eggert A, Bornfeld N, Schueler A (2008) Photodynamic therapy in retinoblastoma: effects of verteporfin on retinoblastoma cell lines. Invest Ophthalmol Vis Sci 49(7):3158–3163CrossRefPubMed

30.

Mergler S, Cheng Y, Skosyrski S, Garreis F, Pietrzak P, Kociok N et al (2012) Altered calcium regulation by thermosensitive transient receptor potential channels in etoposide-resistant WERI-Rb1 retinoblastoma cells. Exp Eye Res 94(1):157–173CrossRefPubMed

31.

Pewzner-Jung Y, Tavakoli Tabazavareh S, Grassme H, Becker KA, Japtok L, Steinmann J et al (2014) Sphingoid long chain bases prevent lung infection by Pseudomonas aeruginosa. EMBO Mol Med 6(9):1205–1214CrossRefPubMedPubMedCentral

32.

Japtok L, Schmitz EI, Fayyaz S, Kramer S, Hsu LJ, Kleuser B (2015) Sphingosine 1-phosphate counteracts insulin signaling in pancreatic beta-cells via the sphingosine 1-phosphate receptor subtype 2. FASEB J 29(8):3357–3369

33.

Gulbins E, Palmada M, Reichel M, Luth A, Bohmer C, Amato D et al (2013) Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs. Nat Med 19(7):934–938CrossRefPubMed

34.

Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL (2012) Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics 13:134CrossRefPubMedPubMedCentral

35.

Sobue S, Nemoto S, Murakami M, Ito H, Kimura A, Gao S et al (2008) Implications of sphingosine kinase 1 expression level for the cellular sphingolipid rheostat: relevance as a marker for daunorubicin sensitivity of leukemia cells. Int J Hematol 87(3):266–275CrossRefPubMed

36.

Xia P, Gamble JR, Wang L, Pitson SM, Moretti PA, Wattenberg BW et al (2000) An oncogenic role of sphingosine kinase. Curr Biol: CB 10(23):1527–1530CrossRefPubMed

37.

Sankala HM, Hait NC, Paugh SW, Shida D, Lepine S, Elmore LW et al (2007) Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin. Cancer Res 67(21):10466–10474CrossRefPubMed

Titel: Etoposide Upregulates Survival Favoring Sphingosine-1-Phosphate in Etoposide-Resistant Retinoblastoma Cells
verfasst von: Vinodh Kakkassery
S. Skosyrski
A. Lüth
B. Kleuser
M. van der Giet
R. Tate
J. Reinhard
A. Faissner
S. C. Joachim
N. Kociok
Publikationsdatum: 15.11.2017
Verlag: Springer Netherlands
Erschienen in: Pathology & Oncology Research / Ausgabe 1/2019
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-017-0360-x

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Etoposide Upregulates Survival Favoring Sphingosine-1-Phosphate in Etoposide-Resistant Retinoblastoma Cells

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid

Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients

Downregulated Adhesion-Associated microRNAs as Prognostic Predictors in Childhood Osteosarcoma

Possible Predictive Markers of Response to Therapy in Esophageal Squamous Cell Cancer

Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data

Molecular Subgroups of Glioblastoma– an Assessment by Immunohistochemical Markers

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie